Core Insights - Polyrizon Ltd. announced positive results from a pre-clinical study evaluating its PL-14 Allergy Blocker formulation, demonstrating its effectiveness in blocking allergens compared to hydroxypropyl methylcellulose (HPMC) [1][5]. Study Findings - The study utilized a validated in-vitro Transwell permeability system to assess PL-14's ability to inhibit the transfer of Der p 1, a significant house dust mite allergen associated with allergic rhinitis and asthma [2]. - PL-14 significantly reduced allergen transfer at all time points compared to HPMC, with statistical significance (p-values ≤ 0.0042) observed at 1, 2, 4, 6, and 24 hours [3][9]. - At 1 hour, PL-14 showed a mean allergen concentration of approximately 20.6 ng, while HPMC had a concentration of about 1354.4 ng. By 24 hours, HPMC's concentration rose to around 5201.2 ng, indicating limited barrier function [9]. Product Development - The results support the continued advancement of PL-14 as a preventive approach for allergic rhinitis by reducing allergen penetration through a synthetic surface [6]. - Polyrizon is advancing its preclinical development program and plans to support future clinical studies to establish PL-14's regulatory pathway and clinical benefits for allergy prevention [6]. Company Overview - Polyrizon is a development-stage biotechnology company focused on innovative medical device hydrogels delivered as nasal sprays, creating a barrier against viruses and allergens [7]. - The company's proprietary Capture and Contain TM hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development to enhance bioadhesion and retention for drug delivery [7].

Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA methylation and next-generation precision diagnostics. The Company also outlined a ...

Core Viewpoint - Humacyte, Inc. plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for its acellular tissue engineered vessel (ATEV™ or Symvess) aimed at arterial trauma repair, with expectations for expedited commercialization in other regions following FDA approval [1][2]. Group 1: Expansion Plans - The expansion of Symvess is driven by requests from surgeons and hospitals in Israel, with plans to extend into Europe and the Middle East [1][2]. - The company anticipates that the FDA approval of Symvess will facilitate faster commercialization pathways in these new territories [2]. Group 2: Clinical Data and Product Features - Positive three-year results from the V005 Phase 2/3 study of Symvess in extremity vascular repair provide the first long-term data in traumatic arterial repair using a biologic conduit [2]. - Symvess is designed to be available off-the-shelf, which is crucial for saving surgical time in emergency situations, and has shown low infection rates and high limb salvage rates [2]. Group 3: Company Overview - Humacyte is focused on developing universally implantable bioengineered human tissues and has received FDA approval for its ATEV in December 2024 for vascular trauma [3]. - The company is also conducting late-stage clinical trials for other vascular applications and has received various designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) [3].

Company Overview - Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders [3] - The company is advancing verekitug, a monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), which is involved in inflammatory responses [3] - Verekitug is currently in separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD) [3] Upcoming Events - Rand Sutherland, MD, CEO of Upstream Bio, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. PT [1] - A live webcast of the presentation will be available on Upstream Bio's website, with a replay accessible afterward [2]

Core Insights - Jade Biosciences, Inc. is focused on developing therapies for autoimmune diseases and has outlined its strategic priorities for 2026, including key milestones ahead of the J.P. Morgan Healthcare Conference [1][2] Key Program Updates - JADE101 is a fully human monoclonal antibody targeting APRIL, currently in Phase 1 trials, showing high binding affinity and engineered for extended half-life, aiming for patient-friendly dosing [3][4] - JADE201, an anti-BAFF-R monoclonal antibody, is set to enter first-in-human studies in rheumatoid arthritis patients in Q2 2026, with interim data expected in 2027 [5][8] - JADE301, a newly nominated development candidate, is in preclinical development with a Phase 1 trial expected to start in the first half of 2027 [6][14] Upcoming Milestones - Interim results from the JADE101 Phase 1 trial are expected in the first half of 2026, which will inform dose selection for subsequent trials [7] - The Phase 2 clinical trial for JADE101 in IgA nephropathy patients is anticipated to begin mid-2026, with preliminary data expected in 2027 [6][7] - JADE201's first-in-human study is expected to begin in Q2 2026, with interim data anticipated in 2027 [14] Financial Update - As of December 31, 2025, Jade expects to report approximately $336 million in cash and equivalents, providing operational runway into the first half of 2028 [9][10]

Core Viewpoint - ProPhase Labs, Inc. is addressing recent stock price volatility attributed to technical factors, including convertible debt conversion and a reverse stock split, while emphasizing the stability of its underlying asset value [2][3][5]. Group 1: Stock Price Volatility - The company believes that recent stock price fluctuations are due to short-term technical factors, such as the conversion and resale of convertible debt and the transition from Nasdaq to the OTC market [2]. - Over $3.3 million of the $3.8 million convertible debt has been converted, leading to a reduction in company debt and an increase in shareholders' equity [3]. - The remaining unconverted balance of convertible debt is less than $500,000, and recent conversions occurred at a price of approximately $0.76 per share, which is above the current trading price [4]. Group 2: Financial Health and Asset Value - The conversion of debt has increased the number of outstanding shares but has also reduced liabilities, thereby strengthening the company's balance sheet [5]. - The intrinsic value of ProPhase Labs' assets remains unchanged despite the capital structure changes, with significant underlying value in its operating subsidiaries and assets [5]. - The company is focused on stabilizing its capital structure and advancing core business operations, indicating that recent trading volatility does not reflect changes in long-term strategy or growth prospects [5]. Group 3: Company Overview - ProPhase Labs is a biotech and consumer products company focused on innovative healthcare solutions, including Whole Genome Sequencing and diagnostic tests [7]. - The company aims to revolutionize healthcare and is committed to executional excellence and smart diversification [7].

Core Insights - Insilico Medicine, a newly listed biotech firm in Hong Kong, is set to receive up to US$888 million from a partnership with French drug maker Servier to utilize its AI platform for cancer drug development [1][2] - The partnership includes up to US$32 million in upfront and near-term R&D payments, with additional payments based on achieving specific milestones [2] - Insilico's AI-driven drug discovery platform can potentially reduce drug development timelines to 12 to 18 months, compared to the traditional average of 4.5 years [3] Company Overview - Insilico Medicine's IPO raised HK$2.28 billion (US$293 million) and was oversubscribed 1,427 times, indicating strong market interest [1] - The company's generative AI platform creates new drug molecules from scratch by interpreting genomics and biological data, rather than screening existing chemical libraries [4] - Insilico's shares experienced a slight decline of 0.7% to HK$37.30 shortly after the IPO [4] Industry Context - The partnership with Servier highlights a growing trend in the healthcare sector, where companies are increasingly leveraging advanced technologies to meet unmet medical needs [5] - The Hong Kong stock exchange has seen a surge in healthcare listings, driven by favorable policies and collaborations between mainland drug developers and global pharmaceutical companies [4]

Core Viewpoint - The 2025 IPO market shows significant recovery compared to the low point in 2024, with a total of 297 IPOs across A-shares, Hong Kong, and the US markets, marking a notable increase in activity [2][51]. Group 1: IPO Market Overview - The Hong Kong market emerged as the largest IPO market globally in 2025, with 117 companies listed, a nearly 70% increase from 69 in 2024 [2][52]. - A-shares also saw a recovery, with 113 companies listed, up 13% from 100 in 2024, raising a total of 131.77 billion yuan, a 95.6% increase from 673.53 billion yuan in 2024 [52]. - The US market for Chinese companies remained subdued, with only 67 companies listed, raising approximately 8.03 billion yuan, significantly lower than the 18.56 billion yuan in 2024 [53]. Group 2: Investment Institutions - The "TOP100" list for 2025 includes 17 institutions that made the list for the first time in six years, while 18 institutions have maintained their presence for six consecutive years [51]. - The average number of IPO projects per institution in the TOP100 was 4.85, up from 3.19 in 2024, indicating a recovery in market activity [51]. - The threshold for inclusion in the TOP100 was set at 2 IPO projects, compared to 1 in 2024 [51]. Group 3: Fundraising and Project Distribution - The total fundraising amount in the Hong Kong market reached 261.53 billion yuan, a 218.6% increase from 82.1 billion yuan in 2024 [52]. - The average fundraising size for IPOs in Hong Kong was 2.255 billion yuan, significantly higher than 1.19 billion yuan in 2024 [56]. - The top fundraising projects included Ningde Times, which raised 37.701 billion yuan, followed by Zijin Mining and Sany Heavy Industry [57]. Group 4: City and Industry Distribution - In 2025, 89 cities in mainland China and Hong Kong hosted IPO projects, with Shanghai leading at 27 projects, followed by Beijing with 21 and Shenzhen with 16 [58]. - The most active industries for IPOs were biomedicine (26 projects), hardware equipment (25 projects), and software services (22 projects), reflecting the focus on AI technology [61]. - The total fundraising in the electrical equipment sector reached 53.03 billion yuan, driven by leading companies like Ningde Times [61].

Core Viewpoint - New to The Street is a long-running business television platform that showcases emerging growth companies and market innovators, providing them with a credible platform to articulate their business models and market opportunities [2][3][6]. Group 1: Show Details - The upcoming broadcast, Show No. 712, will air tonight at 6:30 PM EST on Bloomberg Television as sponsored programming [2][7]. - Featured companies in this episode include NEONC Technologies, SAGTEC GLOBAL, FLOKI, and ZENITH Prep Academy, each providing insights into their respective industries [2][9]. Group 2: Company Overview - New to The Street has been operational for 17 years, delivering a differentiated media model that allows companies to communicate their strategies and innovations effectively [3][6]. - The platform is recognized for its long-form interviews that focus on business models, innovation, and milestones, avoiding speculation [10]. Group 3: Digital Presence - Beyond television, New to The Street has a significant digital footprint, ranking second in reach within the financial media category on YouTube, only behind The Wall Street Journal [8]. - The platform's flagship channel reaches millions of subscribers globally, extending the impact of each broadcast beyond its initial airing [8].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights on product sales, forecasts for major pharmaceutical companies, integrated financial statements, discounted cash flow analysis, and market-specific analyses [1]